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Summary
Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line 
chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was 
to determine the benefit derived from second-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy 
in advanced biliary tract cancer.
Methods The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in 
managing biliary tract cancer across the UK. Adult patients (aged ≥18 years) who had histologically or cytologically 
verified locally advanced or metastatic biliary tract cancer (including cholangiocarcinoma and gallbladder or 
ampullary carcinoma) with documented radiological disease progression to first-line cisplatin and gemcitabine 
chemotherapy and an Eastern Cooperative Oncology Group performance status of 0–1 were randomly assigned (1:1) 
centrally to active symptom control (ASC) and FOLFOX or ASC alone. FOLFOX chemotherapy was administered 
intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², L-folinic acid 175 mg [or folinic 
acid 350 mg], fluorouracil 400 mg/m² [bolus], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous 
infusion). Randomisation was done following a minimisation algorithm using platinum sensitivity, serum 
albumin concentration, and stage as stratification factors. The primary endpoint was overall survival, assessed in 
the intention-to-treat population. Safety was also assessed in the intention-to-treat population. The study is 
complete and the final results are reported. This trial is registered with ClinicalTrials.gov, NCT01926236, 
and EudraCT, 2013-001812-30.
Findings Between March 27, 2014, and Jan 4, 2018, 162 patients were enrolled and randomly assigned to ASC plus 
FOLFOX (n=81) or ASC alone (n=81). Median follow-up was 21·7 months (IQR 17·2–30·8). Overall survival was 
significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival 
of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone 
group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031). The overall survival rate in the ASC alone group 
was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% 
(39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group. Grade 3–5 adverse 
events were reported in 42 (52%) of 81 patients in the ASC alone group and 56 (69%) of 81 patients in the ASC plus 
FOLFOX group, including three chemotherapy-related deaths (one each due to infection, acute kidney injury, and 
febrile neutropenia). The most frequently reported grade 3–5 FOLFOX-related adverse events were neutropenia 
(ten [12%] patients), fatigue or lethargy (nine [11%] patients), and infection (eight [10%] patients).
Interpretation The addition of FOLFOX to ASC improved median overall survival in patients with advanced biliary 
tract cancer after progression on cisplatin and gemcitabine, with a clinically meaningful increase in 6-month and 
12-month overall survival rates. To our knowledge, this trial is the first prospective, randomised study providing 
reliable, high-quality evidence to allow an informed discussion with patients of the potential benefits and risks from 
second-line FOLFOX chemotherapy in advanced biliary tract cancer. Based on these findings, FOLFOX should 
become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference 
regimen for further clinical trials.
Funding Cancer Research UK, StandUpToCancer, AMMF (The UK Cholangiocarcinoma Charity), and The Christie 
Charity, with additional funding from The Cholangiocarcinoma Foundation and the Conquer Cancer Foundation 
Young Investigator Award for translational research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
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Introduction 
Biliary tract cancer is a term that includes cholangio­
carcinoma (either intrahepatic or extrahepatic in origin) 
and cancers of the gallbladder and ampulla of Vater. These 
uncommon cancers arising from the biliary tract account 
for less than 1% of all cancers worldwide.1 However, its 
incidence is increasing, primarily due to a rising incidence 
of intrahepatic cholangiocarcinoma. The prognosis is 
poor, with an all­stage 5­year overall survival of less 
than 20%.1 Patients are rarely diagnosed with early­stage 
disease and therefore curative surgery and adjuvant 
therapy is only feasible for a small proportion of patients.
The ABC­02 study established cisplatin and 
gemcitabine as first­line therapy for patients with 
advanced biliary tract cancer2 and remains the current 
standard of care. Randomised studies during the past 
decade have failed to show an improvement in survival 
with the addition of biological therapies (EGFR or VEGF 
inhibitors); intensification of chemotherapy is under 
evaluation (eg, gemcitabine, cisplatin, and nab­paclitaxel; 
cisplatin, gemcitabine, and S­1; and FOLFIRINOX 
[oxaliplatin, leucovorin, irinotecan, and fluorouracil]).3–5
The role of second­line chemotherapy after progression 
on cisplatin and gemcitabine remains unclear, with no 
prospective randomised trials reported so far.6,7 Patients 
with advanced biliary tract cancer often experience a rapid 
decline in performance status following progression 
on first­line chemotherapy, and only 15–25% receive 
second­line therapy.2,8,9 Some studies suggest that second­
line chemotherapy might be of value for patients with a 
good performance status;8,10–12 however, this theory is 
subject to selection bias and has not been explored in a 
randomised study, and no consensus exists regarding the 
optimum regimen.
Three groups of agents have broadly shown activity in 
biliary tract cancer in retrospective and prospective trials: 
gemcitabine, fluoropyrimidines, and platinum agents.13 
Since the sensitivity to platinum agents in these 
malignancies is well described,2 together with the fact 
that switching to a fluoropyrimidine­based schedule 
after progression on first­line gemcitabine­based chemo­
therapy is considered appropriate in similar scenarios,14 it 
was anticipated that a fluorouracil and platinum doublet 
(such as oxaliplatin and fluorouracil in FOLFOX, which 
comprises leucovorin, fluorouracil, and oxaliplatin) was 
most likely to be effective. Existing phase 2 and 
retrospective data also supported this choice.6
Novel molecular targets such as fibroblast growth 
factor receptor­2 (FGFR2) fusions and isocitrate 
dehydrogenase­1 (IDH1) mutations have been identified 
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Research in context
Evidence before this study
A previous systematic review by this group published in 2014 
evaluated the level of evidence for the use of second-line 
chemotherapy for patients with advanced biliary tract cancer. 
As part of this systematic review, we searched MEDLINE using the 
search terms “[(((biliary tract AND chemotherapy AND second) 
OR (biliary tract AND chemotherapy AND refractory)) OR 
(gallbladder AND chemotherapy AND refractory)) OR 
(cholangiocarcinoma AND chemotherapy AND refractory)]”, 
with no publication date or language restrictions. Abstracts of the 
Proceedings of the Annual Meeting of the American Society of 
Clinical Oncology, the European Society of Medical Oncology 
Congress since 2002, and the annual World Gastrointestinal 
Congress since 2006 were searched manually. Up to December, 
2013, 25 studies were identified, which were mainly phase 2 
clinical trials and retrospective series. No randomised phase 3 
studies were identified. When this search of the literature was 
updated in December, 2020, phase 3 trial-based evidence 
supporting the role of cytotoxic chemotherapy in this setting was 
still nonexistent. Therefore, before this study, it was not possible 
to reliably determine the real benefit from second-line 
chemotherapy in this setting. Moreover, there was insufficient 
evidence to recommend a specific second-line chemotherapy 
schedule in advanced biliary tract cancer.
Added value of this study
To our knowledge, ABC-06 is the first trial to compare active 
symptom control alone with active symptom control 
combined with FOLFOX chemotherapy following progression 
on first-line treatment with cisplatin and gemcitabine for 
patients with advanced biliary tract cancer. The study met its 
primary endpoint and confirmed that patients who received 
FOLFOX chemotherapy had a longer overall survival, with a 
clinically meaningful increase in 6-month and 12-month 
overall survival rates, than those who received active 
symptom control alone. This outcome was achieved with an 
acceptable toxicity profile. Ongoing quality of life, health 
economics, and translational analyses of ABC-06 will help us 
to understand both the impact on patients’ experience and 
the cost-benefit of FOLFOX chemotherapy in this setting, 
and the mechanisms of primary and secondary resistance to 
this treatment.
Implications of all the available evidence
To our knowledge, this study is the first prospective, 
adequately powered, randomised trial exploring the role of 
chemotherapy in this setting, thus providing reliable 
high-quality evidence to allow an informed discussion with 
patients of the potential benefits and risks from second-line 
FOLFOX chemotherapy in advanced biliary tract cancer. 
Based on the results of ABC-06, FOLFOX should become 
standard-of-care chemotherapy in second-line treatment for 
advanced biliary tract cancer and the reference regimen for 
further clinical trials.
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as promising within phase 2 and phase 3 trials, 
respectively, showing benefit in the second­line setting 
for a selected population of patients harbouring such 
aberrations (mainly those with intrahepatic cholangio­
carcinoma, with approximately 15% prevalence of 
each).15–18 However, active symptom control (ASC), 
including early identification and management of biliary 
tract and cancer­related complications and symptom 
management arising from tumour progression, is the 
current standard of care for most patients diagnosed 
with advanced biliary tract cancer who have progressed 
following first­line chemotherapy, especially in the 
absence of targetable molecular alterations.6
The ABC­06 study aimed to determine if patients with 
advanced biliary tract cancer benefit from the addition of 
second­line FOLFOX to ASC, following progression to 
previous first­line treatment with cisplatin and 
gemcitabine.
Methods 
Study design and participants 
The ABC­06 clinical trial was a phase 3, open­label, 
randomised controlled study conducted under the 
auspices of the UK National Cancer Research Institute 
Upper Gastrointestinal Cancer Studies Group. Patients 
were recruited across 20 centres with expertise in 
managing biliary tract cancer in the UK (appendix p 17).
Patients were eligible if they were aged 18 years or older 
and had histologically or cytologically verified locally 
advanced or metastatic biliary tract cancer (including 
cholangiocarcinoma, gallbladder carcinoma, and ampul­
lary carcinoma) with documented radio logical disease 
progression to previous first­line cisplatin and gemcitabine 
chemotherapy. Any other form of first­line systemic 
chemotherapy or additional line of first­line chemotherapy 
(including rechallenge with cisplatin and gemcitabine) 
was not allowed. Patients who had been started on first­
line cisplatin and gemcitabine for whom the cisplatin was 
stopped due to toxicity (with continuation of gemcitabine) 
were eligible.
A maximum of 6 weeks was allowed between disease 
progression to first­line treatment and the start of 
second­line chemotherapy as part of the ABC­06 trial. All 
patients had to have an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0–1, life expectancy 
of longer than 3 months, and adequate haematological, 
renal, and hepatic function, with no evidence of ongoing 
infection or inadequate biliary drainage. Patients with 
clinical evidence of metastatic disease to the brain and 
those with clinically significant cardiovascular disease 
were excluded. Full details of the patient inclusion and 
exclusion criteria are in the protocol (see appendix).
Trial data were collected and monitored at each site, 
and underwent quality control and analysis at the 
Manchester Clinical Trials Unit (CTU; Manchester, UK). 
The study was sponsored by The Christie NHS 
Foundation Trust and conducted in accordance with the 
principles of Good Clinical Practice and the Declaration 
of Helsinki. The study protocol was approved by a 
research ethics committee and all patients were required 
to provide written, informed consent before any trial­
related investigations or treatment took place.
Randomisation and masking 
This was an open­label study, with no masking. Patients 
were randomly assigned (1:1) to ASC plus FOLFOX or 
ASC alone. Researchers contacted a central telephone 
number whereupon CTU staff used a computer system 
employing a minimisation algorithm over the margins of 
three factors to determine the allocation. Allocations 
were made with a probability of 0·75 to the group that 
would yield improved balance or 0·5 if balance scores 
were tied. Allocations were revealed to the CTU staff 
member only after all the participant details had been 
committed to the system. The allocation was then relayed 
verbally to the caller and an automated confirmation 
e­mail was sent to the recruiting site.
Platinum sensitivity (sensitive vs refractory or resistant), 
serum albumin concentration (<3·5 mg/L vs ≥3·5 mg/L), 
and disease stage (locally advanced vs metastatic) were 
used as stratification factors.8,11,19,20 The definition of 
platinum sensitivity was derived from first­line cisplatin 
and gemcitabine data based on the difference between 
median progression­free survival and time on chemo­
therapy from the ABC­02 clinical trial (approximately 
3 months).2 Platinum sensitivity was defined as sensitive 
(progression after 90 days of day 1 of the last cycle 
of first­line cisplatin and gemcitabine), refractory 
(progression during first­line cisplatin and gemcitabine), 
or resistant (progression within the first 90 days after 
completion of day 1 of the last cycle of first­line cisplatin 
and gemcitabine). Disease stage was defined as locally 
advanced versus metastatic as per the American Joint 
Committee on Cancer staging (version 7),21 according to 
which intrahepatic cholangio carcinoma with multifocal 
or satellite liver lesions or metastases were classified as 
locally advanced in the absence of extrahepatic metastatic 
disease. Although performance status22 is a widely 
recognised prognostic factor in advanced biliary tract 
cancer,8,11,12,19 since only patients with ECOG performance 
status 0–1 were eligible, serum albumin concentration 
was included as a stratification factor instead.11,23
Procedures 
ASC consisted of early identification and treatment of 
biliary­related complications and cancer­related symptom 
management; it could include (and was not limited to) 
the following as per requirements of individual patients: 
biliary drainage, antibiotics, analgesia, steroids, anti­
emetics, other palliative treatment for symptom control, 
palliative radiotherapy (eg, for painful bone metastases), 
and transfusion of blood products.
Patients allocated to the ASC plus FOLFOX group also 
received FOLFOX chemotherapy every 2 weeks for a 
For more on the Upper 
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maximum of 12 cycles. Treatment took place over 2 days, 
and consisted of oxaliplatin 85 mg/m² (in 250–500 mL 
of 5% glucose; 2­h intravenous infusion), L­folinic acid 
175 mg (or folinic acid 350 mg; 2­h intravenous infusion 
concurrently with oxaliplatin infusion), and fluorouracil 
400 mg/m² (5–10 min bolus) completed on day 1, and 
fluorouracil 2400 mg/m² as continuous intravenous 
infusion starting on day 1 and finishing on day 2. At the 
investigator’s discretion, fluorouracil could be started at 
80% of the full dose (with full­dose oxaliplatin) for 
patients older than 70 years. The dose of oxaliplatin 
could be adjusted to 65 mg/m² if the creatinine clearance 
was 30–60 mL/min. It was recommended that the body 
surface area be capped at 2·2 m² for this study, and to be 
recalculated in case of weight variation of greater 
than 5%. From cycle 2 onwards, patients were required 
to have a neutrophil count of at least 1·5 × 10⁹ per L and 
platelet count of at least 75 × 10⁹ per L for chemotherapy 
to proceed. Anti­emetic and supportive medication was 
administered following local protocols. Chemotherapy 
continued (in the absence of disease progression, 
intolerable toxicity, or patient choice to withdraw) up to a 
maximum of 12 cycles (6 months) and patients continued 
with ASC visits every 4 weeks thereafter. A maximum of 
two dose reduction levels per drug were allowed: level −1 
represented a 20% reduction from the full initial dose 
of each drug while level −2 represented a 50% reduction. 
If level −2 was not adequately tolerated for a specific 
drug, that drug was discontinued. If oxaliplatin was 
discontinued due to toxicity, treatment could continue 
with fluorouracil and folinic acid or L­folinic acid alone 
if deemed appropriate by the local investigator. In that 
case, the dose per m² of fluorouracil could be increased 
as per local practice at the discretion of the investigator. 
When a treatment delay was needed because of toxicity, 
the patient was evaluated weekly and the drug restarted 
if the toxicity recovered to grade 1 or lower. If there were 
more than 28 days of treatment delay, the patient 
received no further protocol­mandated treatment. 
Patients with drawn from protocol treatment who agreed 
to continue on study were still followed up until study 
end and details of further treatment given outside the 
trial were recorded.
All patients were seen every 4 weeks for ASC, and 
those receiving chemotherapy were seen every 2 weeks 
for FOLFOX chemotherapy. During these clinic visits, 
physical examination, assessment of ECOG perfor­
mance status, symptom monitoring, reviewing of 
concomitant medication, and assessment of liver and 
renal function with full blood count was done. Adverse 
events were collected at every clinic visit and were 
classified according to the Common Terminology 
Criteria for Adverse Events version 4.03, with causality 
assigned by treating investigators or delegated clinicians. 
Tumour marker (CA19­9, carcinoembryonic antigen, 
and CA125) and C­reactive protein assessments were 
done at baseline and at every follow­up appointment.
Patients in the ASC plus FOLFOX group underwent 
radiological tumour evaluation by CT (and optional 
MRI if clinically indicated) 12 weeks after the start of 
chemotherapy, at the end of chemotherapy, and every 
3 months thereafter until documentation of disease 
progression. All radiological evaluations were investi­
gator assessed, with no central review. Patients assigned 
to ASC alone did not have regular radiological tumour 
evaluation; imaging was allowed as clinically indicated. 
Biliary tract obstruction in itself did not constitute 
evidence of disease progression. Disease response to 
therapy and progression was defined according to 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 in the ASC plus FOLFOX group undergoing 
radiological follow­up.24
In patients with disease progression after ASC plus 
FOLFOX, subsequent treatment was administered at the 
treating clinician’s discretion, including experi mental 
therapies in the context of phase 1 clinical trials. Patients 
assigned to ASC alone were permitted to receive treat­
ment with experimental therapies in the context of 
phase 1 clinical trials.
Quality of life and health status questionnaires 
(European Organisation for Research and Treatment of 
Cancer [EORTC] Quality of Life Questionnaire [QLQ] 30,25 
EORTC QLQ­BIL21,26,27 and EQ­5D28) were used for 
quality­of­life analyses, the results of which will be 
reported separately.
Archival tissue and prospective blood samples (whole 
blood, serum, and plasma) were collected for all 
patients at baseline and at 12 weeks, and were collected 
upon disease progression for patients in the ASC plus 
FOLFOX group for future translational research. For 
patients with HIV, hepatitis C, or other transmissible 
human diseases, blood sample collection did not take 
place. All samples were stored in the Manchester 
Cancer Research Centre Biobank (Manchester, UK; 
Human Tissue Authority licence number 30004; South 
Manchester Research Ethics Committee reference 
number 18/NW/0092).
The independent data monitoring committee did 
an early safety review on Sept 30, 2015, of the first 
20 patients in the ASC plus FOLFOX group who 
had completed one cycle. Additionally, because of 
the concern that patients’ disease might be platinum 
resistant after having progressed on a previous 
platinum regimen, the com mittee was specifically 
asked at the same review to consider whether a change 
in regimen to a non­platinum containing regimen was 
required in the event of futility. The committee 
concluded that no change was required and the trial 
could proceed.
The end of the trial was defined as completion of 
12 months after the date of enrolment of the last patient 
included, or after the death of all the patients, whichever 
happened first. Patients were able to withdraw consent 
from the trial at any time if they wished.
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Outcomes 
The primary endpoint was overall survival, defined as the 
time from randomisation to death from any cause. 
Secondary endpoints were progression­free survival 
(time between randomisation and radiological disease 
progression or death of any cause, whichever occurred 
first) and radiological response as per RECIST version 1.1 
for the ASC plus FOLFOX group only; and assessment of 
adverse events, quality of life, and health economics in 
both groups. Outcomes and toxicity findings are provided 
in this Article; data on quality of life and health economics 
will be reported separately.
Statistical analysis 
The study was powered to show a benefit in overall survival 
with the addition of FOLFOX to ASC in the intention­to­
treat population. 148 death events were required for a 
hypothesised hazard ratio (HR) of 0·63 with 80% power 
and 5% two­sided α; since minimal (<3%) loss to follow­up 
was envisaged, the required sample size was 162 patients. 
At the time of the study design, the assumed 12­month 
overall survival rate for patients assigned to ASC alone 
was 10% (derived from the 24­month overall survival rate 
from the cisplatin and gemcitabine group in the ABC­02 
study,2 given that the first 12 months were taken up with 
first­line effect), and the median overall survival was 
assumed to be 4 months (derived from the difference 
between overall survival [12 months] and progression­free 
survival [8 months] in the ABC­02 study2). The hypothesised 
HR was equivalent to an increase in median overall 
survival from 4 months to 6·4 months.
The study was expected to recruit across 20 centres and 
recruitment was expected to be completed in 28 months 
(from February, 2014, to August, 2016). Because of slower 
than anticipated recruitment, the study period was 
extended to allow the required sample size to be reached 
(protocol version 6.0; July 26, 2017). From the start of 
recruitment to final analysis of the findings, eight 
protocol amendments were submitted and approved 
(appendix p 2). None of these amendments affected the 
sample size or primary or secondary endpoints. The final 
study protocol (version 7.0) is available in the appendix.
Analysis of the primary endpoint (overall survival) was 
done with multivariable Cox regression adjusted for 
the stratification factors (platinum sensitivity, serum 
albumin concentration, and disease stage); HRs for each 
stratification factor are also provided, adjusted by the 
other stratification factors and treatment group. 
Proportional hazard assumptions were assessed with 
plots of Schoenfeld residuals and one­step tests on trend. 
No interim analysis of the primary endpoint was planned. 
Median overall survival, progression­free survival, and 
survival rates at 3 months (progression­free survival) and 
at 6 and 12 months (both progression­free survival 
and overall survival) were derived from Kaplan­Meier 
estimates. Surviving patients were censored at their time 
of last follow­up. Radiological response data were 
summarised by best recorded response, complete 
response, partial response, stable disease, progressive 
disease, or death. Efficacy and safety analyses were done 
in the intention­to­treat population.
Prespecified subgroup analyses by stratification factors 
for overall survival and progression­free survival were 
done, together with post­hoc subgroup analyses by 
primary tumour site and ECOG performance status. A 
post­hoc sensitivity analysis for overall survival using the 
stratification categories provided by local investigators at 
the time of randomisation was also done.
Two­sided p<0·05 was considered signifi cant. Stata 
(version 15.1) was used for statistical analysis. The final 
database extraction for analysis was done on April 3, 2020. 
The study was registered as an interventional randomised 
open­label trial with ClinicalTrials.gov, NCT01926236, 
and EudraCT, 2013­001812­30.
Role of the funding source 
The funders for this academic investigator­initiated study 
provided input in the form of peer review to ensure 
patient acceptability but had no role in study design in 
conception. The study sponsor (The Christie NHS 
Foundation Trust) provided regulatory and governance 
oversight with no direct involvement in design or data 
81 included in intention-to-treat analysis 81 included in intention-to-treat analysis







 9 reason not specified
81 randomly assigned to ASC alone
 8 received off-study chemotherapy
2 lost to follow-up (patient decision) with
 <3 months of follow-up
81 randomly assigned to ASC plus FOLFOX
 75 received FOLFOX
 9 received only one cycle
 6 did not receive FOLFOX
1 lost to follow-up (patient uncontactable)
 after 13·3 months
24 excluded
 21 ineligible
 2  withdrew consent
 1 died
Figure 1: Trial profile
ASC=active symptom control. FOLFOX=folinic acid, fluorouracil, and oxaliplatin.
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collection, analysis, or interpretation. The sponsor was 
not involved in the writing of the study report, although 
has approved the final version. 
Results 
Between March 27, 2014, and Jan 4, 2018, 290 patients 
were assessed for eligibility, of whom 162 patients from 
20 sites in the UK were randomly assigned to ASC alone 
(n=81) or ASC plus FOLFOX (n=81; figure 1). The end of 
the follow­up of the last patient recruited, and thus the 
end of the study, was reached on Jan 4, 2019. At data cutoff, 
the median follow­up was 21·7 months (IQR 17·2–30·8).
In all enrolled patients, the primary tumour sites 
were intrahepatic cholangiocarcinoma (in 72 [44%] of 
162 patients), extrahepatic cholangiocarcinoma (45 [28%]), 
gallbladder (34 [21%]), and ampullary cancer (11 [7%]). 
Baseline characteristics were generally well balanced 
between study groups (table 1).
By data cutoff, 150 patients had died: 74 in the ASC alone 
group and 76 in the ASC plus FOLFOX group. Median 
overall survival was 6·2 months (95% CI 5·4–7·6) in the 
ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in 
the ASC alone group (adjusted HR 0·69 [95% CI 
0·50–0·97], p=0·031; figure 2). The overall survival rate in 
the ASC alone group was 35·5% (95% CI 25·2–46·0) at 
6 months and 11·4% (5·6–19·5) at 12 months, compared 
with 50·6% (39·3–60·9) at 6 months and 25·9% 
(17·0–35·8) at 12 months in the ASC plus FOLFOX group. 
No evidence was identified against the key proportional 
hazards assumption (proportional hazards assumption 
test p=0·65).
The other factors included in the multivariable analyses 
for overall survival were platinum sensitivity (adjusted 
HR 0·71, 0·49–1·00; p=0·050), high albumin at baseline 
(0·54, 0·37–0·78; p=0·0010), and metastatic disease 
(1·33, 0·85–2·09; p=0·21).
At the time of data cleaning and quality­control checks, 
stratification errors were identified with incorrect 
baseline information provided by study sites at the time 
of randomisation. A post­hoc sensitivity analysis for 
overall survival using the categories provided by local 
investigators at the time of randomisation confirmed the 
beneficial effect of FOLFOX plus ASC versus ASC alone 
on overall survival (adjusted HR 0·68, 95% CI 0·49–0·95; 
p=0·022; appendix p 3).
78 (96%) of 81 patients assigned to ASC plus FOLFOX 
had disease progression or had died at the time of data 
analysis. Median progression­free survival was 4·0 months 
(95% CI 3·2–5·0; appendix p 4). The progression­free 
survival rate was 66·7% (95% CI 55·3–75·8) at 3 months, 
32·1% (22·3–42·3) at 6 months, and 8·6% (3·8–16·0) at 
12 months. Objective response was observed in four (5%) 
of 81 patients in the ASC plus FOLFOX group: one (1%) 
patient had a complete response and three (4%) patients 
had a partial response. One (1%) patient did not have 
measurable disease, but was included in the analysis 
for evaluation of progression or stabilisation. Disease 
control was observed in 27 (33%) of 81 patients, including 
23 (28%) patients with stable disease. The remaining 
53 patients were non­responders: 30 (37%) patients had 
ASC alone group  
(n=81)
ASC plus FOLFOX 
group (n=81)
Sex
Female 44 (54%) 38 (47%)
Male 37 (46%) 43 (53%)
Age, years
Median 65 (59–72) 65 (59–72)
Range 26–81 26–84
Platinum sensitivity*
Resistant or refractory† 47 (58%) 54 (67%)
Sensitive 34 (42%) 27 (33%)
Albumin*
<35 g/L 21 (26%) 19 (23%)
≥35 g/L 60 (74%) 62 (77%)
Disease stage*
Locally advanced 15 (19%) 14 (17%)
Metastatic 66 (81%) 67 (83%)
Tumour site
Intrahepatic 38 (47%) 34 (42%)
Extrahepatic 19 (23%) 26 (32%)
Gallbladder 17 (21%) 17 (21%)
Ampulla 7 (9%) 4 (5%)
Histology
Adenocarcinoma 74 (91%) 73 (90%)
Other‡ 7 (9%) 8 (10%)
Grade of differentiation
Well 5 (6%) 9 (11%)
Moderately 41 (51%) 37 (46%)
Poorly 11 (14%) 9 (11%)
Not specified 23 (28%) 26 (32%)
Missing 1 (1%) 0
ECOG performance status
0 28 (35%) 25 (31%)
1 52 (64%) 55 (68%)
Missing 1 (1%) 1 (1%)
Had previous surgery 38 (47%) 34 (42%)
Previous cisplatin and gemcitabine
Duration, months 4·8 (2·9–5·3) 4·9 (2·8–5·5)
≥6 months 6 (7%) 13 (16%)§
Baseline CA19.9 (U/mL)¶ 443 (46–5714) 162 (25–1903)
Baseline carcinoembryonic antigen (U/mL)¶ 6 (3–16) 6 (3–24)
Baseline CA125 (U/mL)¶ 42 (20–168) 52 (21–159)
Data are n (%) or median (IQR). ASC=active symptom control. FOLFOX= folinic acid, fluorouracil, and oxaliplatin. 
ECOG=Eastern Cooperative Oncology Group. *Stratification factors. †26 patients in the ASC alone group and 
36 patients in the ASC plus FOLFOX group had platinum refractory disease. 21 patients in the ASC alone group and 
18 patients in the ASC plus FOLFOX group had platinum-resistant disease. ‡Other included squamous, 
adenosquamous, and not specified. §Five patients were platinum sensitive, seven platinum resistant, and one 
platinum refractory. ¶Baseline tumour marker data were available for 67 (ASC alone) and 68 (ASC plus FOLFOX) 
patients for CA19.9, 76 (ASC alone) and 76 (ASC plus FOLFOX) patients for carcinoembryonic antigen, and 
71 (ASC alone) and 72 (ASC plus FOLFOX) patients for CA125.
Table 1: Baseline characteristics
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disease progression and 23 (28%) patients died. 
Three patients were still free from disease progression 
and alive at time of last follow­up, with individual 
progression­free survival ranging between 13·3 and 
18·4 months; in one of these patients, a maintained 
radiological complete response was observed.
Subgroup analyses of overall survival are shown in 
figure 3. Estimated median overall survival and 
progression­free survival for subgroups of interest are 
shown in the appendix (pp 5–9).
75 (93%) of 81 patients in the ASC plus FOLFOX group 
received at least one cycle of FOLFOX, with six patients 
receiving no chemotherapy for various reasons (some not 
reported). The median number of FOLFOX cycles received 
was five (IQR 2–6), with a median interval between the 
first and last doses received of 70 days (41–111). 46 (61%) of 
75 patients required at least one component of FOLFOX 
chemo therapy to be dose reduced or omitted on one or 
more cycles. 13 (16%) of 81 patients completed all 12 cycles 
of FOLFOX. The main reasons for early discontinuation 
included radiological disease progression (24 patients), 
clinical disease progression (13 patients), intolerable 
toxicity (ten patients), intercurrent illness (five patients), 
patient decision (five patients), investigator decision 
(five patients), or other unspecified reason (three patients).
Grade 3–5 adverse events were reported in 56 (69%) 
of 81 patients in the ASC plus FOLFOX group and 
42 (52%) of 81 patients in the ASC alone group. Three 
chemo therapy­related deaths (one each due to infection, 
acute kidney injury, and febrile neutropenia) were 
reported in the ASC plus FOLFOX group. All other 
deaths reported in both groups were cancer related, 
with the exception of ten deaths associated with 
intercurrent illness (eight in the ASC plus FOLFOX 
group and two in the ASC­only group); cause of death 
was not reported for one patient in the ASC alone group. 
The most frequently reported grade 3–5 chemotherapy­
related adverse events were neutropenia (ten [12%] 
patients), fatigue or lethargy (nine [11%] patients), 
and infection (eight [10%] patients; table 2; figure 4). 
Full details on adverse events are provided in the 
appendix (pp 10–11 for grade 3–5, p 12 for grade 1–2 
adverse events regardless of causality, and p 13 for 
chemotherapy­related serious adverse events for the 
ASC plus FOLFOX group.
Eight (10%) of 81 patients assigned to ASC only 
received off­protocol chemotherapy. 21 (13%) of 
162 patients received some form of subsequent systemic 
anticancer therapy after the trial: five (3%) in the form of 
phase 1 trials and 16 (10%) in the form of chemotherapy 
agents (appendix p 14).
Discussion 
The results of the ABC­06 study show that FOLFOX 
chemotherapy can improve overall survival in patients 
with good performance status with advanced biliary tract 
cancer who have been previously treated with cisplatin 
and gemcitabine. To our knowledge, this trial is the first 
prospective randomised phase 3 study to evaluate the 
additional role of chemotherapy with ASC compared with 
ASC alone in these patients. Although some clinicians 
have already used FOLFOX in this setting, they were 













































































































Adjusted HR 0·69 (95% CI 0·50–0·97);
p=0·031
Figure 2: Overall survival
The HR is adjusted for the three stratification factors (platinum sensitivity, 
serum albumin concentration, and disease stage). ASC=active symptom control. 
FOLFOX=folinic acid, fluorouracil, and oxaliplatin. HR=hazard ratio. *Numbers 
are cumulative.
Figure 3: Subgroup analyses of overall survival
Hazard ratios were adjusted by the three stratification factors (platinum sensitivity, serum albumin 
concentration, and disease stage), or the remaining two stratification factors where the factor of interest was 
itself a stratification factor.  ASC=active symptom control. ECOG=Eastern Cooperative Oncology Group. 
FOLFOX=folinic acid, fluorouracil, and oxaliplatin. *ECOG performance status information was missing for 
one participant (death) in the ASC alone group.
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Grade 1–2 Grade 3 Grade 4 Grade 5












































Any* 35 (43%) 24 (30%) 37 (46%) 35 (43%) 39 (48%) 23 (28%) 3 (4%) 10 (12%) 5 (6%) 4 (5%) 7 (9%) 3 (4%)
Neuropathy 8 (10%) 55 (68%) 52 (64%) 0 1 (1%) 1 (1%) 0 0 0 0 0 0
Fatigue or lethargy 47 (58%) 58 (72%) 47 (58%) 6 (7%) 15 (19%) 9 (11%) 0 0 0 0 0 0
Nausea 32 (40%) 40 (49%) 30 (37%) 1 (1%) 1 (1%) 1 (1%) 0 0 0 0 0 0
Oral mucositis 4 (5%) 29 (36%) 28 (35%) 0 1 (1%) 1 (1%) 0 0 0 0 0 0
Anorexia 31 (38%) 47 (58%) 25 (31%) 6 (7%) 1 (1%) 1 (1%) 0 0 0 0 0 0
Diarrhoea 12 (15%) 27 (33%) 22 (27%) 2 (2%) 2 (2%) 2 (2%) 0 0 0 0 0 0
Thrombocytopenia 1 (1%) 18 (22%) 18 (22%) 0 0 0 0 0 0 0 0 0
Dysgeusia 11 (14%) 23 (28%) 16 (20%) 1 (1%) 0 0 0 0 0 0 0 0
Vomiting 16 (20%) 20 (25%) 14 (17%) 4 (5%) 3 (4%) 2 (2%) 0 0 0 0 0 0
Constipation 28 (35%) 35 (43%) 13 (16%) 1 (1%) 2 (2%) 0 0 0 0 0 0 0
Neutropenia 0 13 (16%) 12 (15%) 1 (1%) 8 (10%) 8 (10%) 0 2 (2%) 2 (2%) 0 0 0
Infection† 17 (21%) 19 (23%) 10 (12%) 3 (4%) 12 (15%) 6 (7%) 0 2 (2%) 1 (1%) 2 (2%) 1 (1%) 1 (1%)
Anaemia 5 (6%) 10 (12%) 9 (11%) 1 (1%) 2 (2%) 2 (2%) 0 0 0 0 0 0
Dry mouth 11 (14%) 20 (25%) 9 (11%) 0 1 (1%) 0 0 0 0 0 0 0
Pain 50 (62%) 42 (52%) 6 (7%) 5 (6%) 8 (10%) 0 1 (1%) 0 0 0 0 0
Tinnitus 2 (2%) 8 (10%) 5 (6%) 0 0 0 0 0 0 0 0 0
Myalgia 5 (6%) 10 (12%) 4 (5%) 1 (1%) 0 0 0 0 0 0 0 0
Oedema 9 (11%) 17 (21%) 4 (5%) 1 (1%) 0 0 0 1 (1%) 0 0 0 0
Dyspnoea 6 (7%) 13 (16%) 3 (4%) 1 (1%) 1 (1%) 0 0 0 0 0 0 0
Muscle weakness 9 (11%) 6 (7%) 3 (4%) 0 0 0 0 0 0 0 0 0
Thromboembolic 
event
2 (2%) 3 (4%) 3 (4%) 4 (5%) 0 0 0 0 0 0 0 0
Cough 4 (5%) 11 (14%) 2 (2%) 0 0 0 0 0 0 0 0 0
Dyspepsia 10 (12%) 8 (10%) 2 (2%) 0 0 0 0 0 0 0 0 0
Weight loss 9 (11%) 8 (10%) 2 (2%) 0 0 0 0 0 0 0 0 0
Abdominal 
distension
7 (9%) 3 (4%) 1 (1%) 0 2 (2%) 0 0 0 0 0 0 0
Biliary event‡ 2 (2%) 2 (2%) 1 (1%) 13 (16%) 13 (16%) 2 (2%) 2 (2%) 2 (2%) 0 2 (2%) 1 (1%) 0
Catheter-related 
infection
0 2 (2%) 1 (1%) 0 2 (2%) 0 0 0 0 0 0 0
Erythema 1 (1%) 2 (2%) 1 (1%) 1 (1%) 0 0 0 0 0 0 0 0
Hypertension 4 (5%) 10 (12%) 1 (1%) 1 (1%) 4 (5%) 2 (2%) 0 0 0 0 0 0
Hypophosphatemia 0 2 (2%) 1 (1%) 1 (1%) 0 0 0 1 (1%) 0 0 0 0
Hypotension 1 (1%) 1 (1%) 1 (1%) 0 1 (1%) 0 0 0 0 0 0 0
Acute kidney injury 2 (2%) 0 0 0 1 (1%) 1 (1%) 0 0 0 0 2 (2%) 1 (1%)
Allergic reaction 0 0 0 0 1 (1%) 1 (1%) 0 0 0 0 0 0
Ascites 2 (2%) 10 (12%) 0 2 (2%) 2 (2%) 0 0 0 0 0 0 0
Cerebrovascular 
ischaemia
0 0 0 0 0 0 0 1 (1%) 0 0 0 0
Dehydration 0 0 0 1 (1%) 0 0 0 0 0 0 0 0
Diabetic 
ketoacidosis
0 0 0 0 0 0 0 0 0 0 1 (1%) 0
Fall 0 0 0 0 1 (1%) 0 0 0 0 0 0 0
Febrile neutropenia 0 0 0 0 0 0 0 1 (1%) 1 (1%) 0 1 (1%) 1 (1%)
Fracture (non-
pathological)
0 0 0 0 1 (1%) 0 0 0 0 0 0 0
(Table 2 continues on next page)
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In the ABC­06 trial, patients who received ASC (which 
was the evidence­based approach in this setting before 
this study) showed a longer survival than expected. This 
has also been reported in two contemporary randomised 
clinical trials, exploring the role of regorafenib (multi­
tyrosine kinase inhibitor)29 and ivosidenib (IDH1 
inhibitor)17 in the second­line setting for patients with 
advanced biliary tract cancer. Both trials contained a 
placebo group, in which the management was similar to 
the ASC approach described here. The reported median 
overall survival for the control groups in those trials was 
5·1 months29 and 6 months17 (when adjusted for 
crossover), respectively. The longer than expected overall 
survival in the ASC or placebo groups might be related to 
patient selection; patients who are fit enough to enter a 
second­line clinical trial are more likely to have a more 
favourable natural history. Nevertheless, this study 
supports the position that even when anticancer 
strategies are not being pursued, ASC (a proactive 
supportive care) rather than reactive management of 
symptoms is of benefit and might improve survival.30
The benefit achieved with the addition of FOLFOX 
chemotherapy in terms of median overall survival might 
seem marginal (lessened by a better than expected overall 
survival in the ASC alone group); this finding has also 
been described in other studies in this setting and might 
reflect the rapid deterioration of some patients before 
treatment has time to have a biological effect.31 However, 
the overall reduction in risk of death and positive impact 
on 6­month and 12­month overall survival rates are 
clinically meaningful. The toxicity profile of FOLFOX 
was tolerable and in line with that described with 
FOLFOX in many other malignancies.
Given the randomised design of this study, the effect of 
adding chemotherapy can be seen clearly. Few other 
clinical trials (none of them phase 3) exploring the role of 
cytotoxic agents (eg, etoposide toniribate [EDO­S7.1],32 
FOLFIRINOX [fluorouracil, irinotecan, and oxaliplatin],33 
and other small molecules [eg, regorafenib]29) have been 
reported in this setting. Although the results from these 
studies are of interest, interstudy comparison is not 
possible because of differences in baseline characteristics, 
Grade 1–2 Grade 3 Grade 4 Grade 5












































(Continued from previous page)
Gastric outlet 
obstruction
0 0 0 1 (1%) 0 0 0 0 0 0 0 0
Gastrointestinal 
bleeding
3 (4%) 1 (1%) 0 2 (2%) 1 (1%) 0 0 0 0 0 0 0
Generalised muscle 
weakness
1 (1%) 0 0 0 1 (1%) 0 0 0 0 0 0 0
Hallucinations 1 (1%) 0 0 0 1 (1%) 0 0 0 0 0 0 0
Hip fracture 0 0 0 1 (1%) 0 0 0 0 0 0 0 0
Hypercalcemia 1 (1%) 1 (1%) 0 1 (1%) 1 (1%) 0 0 1 (1%) 0 0 0 0
Hyperglycaemia 2 (2%) 2 (2%) 0 0 2 (2%) 0 0 0 0 0 0 0
Hypoalbuminemia 1 (1%) 2 (2%) 0 0 1 (1%) 0 0 0 0 0 0 0
Hypokalaemia 0 0 0 0 1 (1%) 1 (1%) 0 0 0 0 0 0
Hyponatremia 2 (2%) 2 (2%) 0 1 (1%) 0 0 0 0 0 0 0 0
Hypoxia 0 0 0 0 1 (1%) 0 0 0 0 0 0 0
Insomnia 6 (7%) 4 (5%) 0 0 1 (1%) 0 0 0 0 0 0 0
Leg oedema 3 (4%) 3 (4%) 0 1 (1%) 0 0 0 0 0 0 0 0
Liver failure 0 0 0 1 (1%) 0 0 0 0 0 0 0 0
Myocardial 
infarction
0 0 0 0 0 0 0 1 (1%) 1 (1%) 0 0 0
Pleural effusion 0 0 0 0 2 (2%) 0 0 0 0 0 0 0
Rhabdomyolisis 0 0 0 0 0 0 0 0 0 0 1 (1%) 0
Adverse events are listed in order of frequency, with the most frequent chemotherapy-related pooled grade 1/2 adverse events listed first. All grade 1–2 adverse events occurring in at least 10% of patients and all 
grade 3, 4, and 5 events are reported. Full details are available in the appendix (p 10). All percentages are calculated by intention to treat. ASC=active symptom control. FOLFOX=folinic acid, fluorouracil, 
and oxaliplatin. *Refers to highest grade overall within-subject adverse events. †Lung, urinary, fever, or not specified, excluding liver or biliary. ‡Includes liver infection, increased bilirubin or alkaline phosphatase, 
and hepatitis.
Table 2: Adverse events and chemotherapy-related toxicity
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such as line of therapy or primary tumour site (appendix 
pp 15–16), some of which are known to affect prognosis.34
Targeted therapies (ie, FGFR2 and IDH1 inhibitors) 
have a potential role in the second­line setting for 
advanced biliary tract cancer. Patients harbouring such 
alterations would be suitable for precision medicine 
strategies and their outcome might be difficult to 
compare with other advanced biliary tract cancers 
without such alterations.18 The natural history of these 
subgroups (including within ABC­06) is not yet fully 
understood and the timing of targeted therapies with 
respect to standard systemic chemotherapy (including 
FOLFOX in second line) is an area for future clinical and 
translational research.
A contentious issue with the ABC­06 clinical trial was 
the fact that it employed a platinum agent (oxaliplatin) 
following disease progression on another platinum 
(cisplatin).35 Platinum drugs are one of the active agents in 
advanced biliary tract cancer, together with gemcitabine 
and fluoropyrimidines.13 The third­generation platinum 
analogue oxaliplatin has activity in several gastrointestinal 
tumours and shows synergistic activity with a favourable 
toxicity profile in combination with fluorouracil that 
differs from the synergies proposed for cisplatin and 
gemcitabine.36 Additionally, non­cross resistance between 
oxaliplatin and cisplatin has been confirmed, although 
remains controversial.37,38 The ABC­06 study showed how 
the overall survival and progression­free survival benefit 
was independent of whether patients were classed as being 
platinum sensitive or platinum refractory or resistant. In 
fact, subgroups with suspected poorer prognosis seemed 
to benefit most from FOLFOX. A potential explanation is 
that those patients with more aggressive tumours are the 
ones deriving more benefit from an aggressive anti­
proliferative therapy such as second­line chemotherapy. 
However, no strong conclusions can be derived in view of 
insufficient statistical power for subgroup analyses. These 
observations highlight the importance of a better under­
standing of the mechanisms behind response to platinum­
based chemotherapy, such as pathways involved in DNA 
damage repair,39 among others.
Our subgroup analysis also showed a weaker overall 
survival benefit from treatment with FOLFOX in the 
extrahepatic cholangiocarcinoma subgroup; however, 
this observation should be viewed with caution owing to 
insufficient statistical power. We would still encourage 
the use of FOLFOX for this patient population following 
progression on cisplatin and gemcitabine.
Limitations of this study include its conduct in a single 
country. However, the magnitude of benefit previously 
observed with first­line cisplatin and gemcitabine chemo­
therapy was consistent across geographical regions,40 and 
this can reasonably also be expected in the second­line 
setting. Additionally, current predominant practice in the 
UK during first­line chemotherapy is to interrupt 
treatment at the completion of 6 months of therapy (as per 
the ABC­02 trial protocol), whereas other countries might 
continue treatment until disease progression. The effect 
of this practice on the efficacy of second­line therapy is not 
yet well understood. Further more, countries have varying 
access to molecular profiling (especially during the time 
this study was recruiting). Routine molecular profiling 
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Figure 4: Grade 3–5 adverse events and chemotherapy-related toxicity
Grade 3–5 adverse events reported at least in 1% of patients in the ASC plus FOLFOX group that were considered to be chemotherapy related are summarised, 
alongside the incidence in each study group regardless of causality. Percentages are calculated in the intention-to-treat population. ASC=active symptom control. 
FOLFOX=folinic acid, fluorouracil, and oxaliplatin. *Includes liver infection, increased bilirubin or alkaline phosphatase, and hepatitis.
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was not available for patients participating in ABC­06 
because it was not protocol driven nor standard of care at 
the time of study conduct; thus, the impact on patients 
with specific molecular aberrations is not known.
We cannot exclude that ASC in the chemotherapy group 
was more meticulous than in the ASC alone group, but we 
considered fortnightly visits for patients not receiving 
chemotherapy too onerous; moreover, this is unlikely to 
have had a substantial effect on overall survival. Primary 
disease site, previous surgery, and ECOG performance 
status were not included as stratification factors since the 
magnitude of benefit from chemotherapy was expected to 
be consistent across these subgroups; since most baseline 
characteristics were well balanced between study groups, it 
is unlikely that having stratified for these factors would 
have affected the study outcome. It is difficult to determine 
whether the differences in pre­treatment CA19.9 between 
study groups is of any relevance, and this should be 
explored in the future. Platinum­refractory and platinum­
resistant patients were analysed together; however, raw 
data would allow for further subsequent analysis (possibly 
via meta­analyses with other studies). Additionally, 
although platinum sensitivity was predefined for ABC­06, 
this definition has not yet been validated in biliary tract 
cancer and should be further interrogated in future 
studies. The insufficient power for subgroup analyses, 
which challenges some interpretations, is an acknow­
ledged limitation, especially in such a heterogeneous 
disease. Routine radiological follow­up of patients assigned 
to the ASC only group was not pursued (because disease 
was likely to be steadily progressive), which limits the 
understanding and interpretation of progression­free 
survival and radiological response data, which are provided 
for the chemotherapy group only. Furthermore, the 
3­monthly imaging, the absence of central radiology 
review, and the open­label design might have affected 
progression­free survival results and interpretation; 
however, the primary endpoint was unlikely to be affected 
by this. Subsequent lines of treatment were administered 
as per clinician discretion and could have affected overall 
survival; however, the proportion of patients receiving 
these was well balanced between the study groups and 
unlikely to affect the primary endpoint.
The ABC­06 clinical trial is, to our knowledge, the 
first randomised phase 3 clinical trial exploring the role 
of second­line chemotherapy in advanced biliary tract 
cancer. It shows a benefit from FOLFOX in terms of 
overall survival, with a meaningful increase in survival 
rates at 6 and 12 months. FOLFOX should therefore be 
considered the standard chemotherapy treatment after 
progression following cisplatin and gemcitabine and 
should be regarded as the reference regimen in future 
clinical trials in this setting.
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